Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer
So far, mAb E48 is the most promising antibody described for specific targeting of head and neck squamous cell carcinoma (HNSCC) in patients. On the basis of its more homogeneous reactivity pattern on HNSCC, the novel mAb U36 may be even better suited for targeting. In this study the biodistribution...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 1995-06, Vol.1 (6), p.591-598 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 598 |
|---|---|
| container_issue | 6 |
| container_start_page | 591 |
| container_title | Clinical cancer research |
| container_volume | 1 |
| creator | DE BREE, R ROOS, J. C QUAK, J. J DEN HOLLANDER, W SNOW, G. B VAN DONGEN, G. A. M. S |
| description | So far, mAb E48 is the most promising antibody described for specific targeting of head and neck squamous cell carcinoma (HNSCC)
in patients. On the basis of its more homogeneous reactivity pattern on HNSCC, the novel mAb U36 may be even better suited
for targeting. In this study the biodistribution of mAb U36 was evaluated by radioimmunoscintigraphy (RIS) and biopsy measurements
in 10 patients who were suspected of having neck lymph node metastases from a histologically proven HNSCC and who had been
scheduled to undergo resection of the primary tumor and neck dissection. Patients received 1.8-53.0 mg mAb U36 IgG labeled
with 756 +/- 95 MBq technetium-99m i.v. Preoperatively, palpation, computerized tomography, magnetic resonance imaging, and
RIS were performed. RIS images included planar and single-photon emission computerized tomography images of the head and neck
and planar images of the whole body. The diagnostic findings were recorded per side as well as per lymph node level of the
neck and compared to the histopathological outcome. Radioactivity in blood samples and biopsies from the surgical specimens
were measured. All 10 primary tumors were visualized by RIS. All diagnostic modalities were correct in 7 of 14 tumor-involved
lymph node levels. The missed lymph node metastases comprised micrometastases, small tumor-involved nodes ( |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_77952407</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77952407</sourcerecordid><originalsourceid>FETCH-LOGICAL-h266t-1c86a34caced7dc6c81f506fe7ca426126b68be32486c8fe49037a95ebf756523</originalsourceid><addsrcrecordid>eNpNkM1q3TAQhU1pSdK0j1DQonRn0I8l2csSmqRwoRCStRlL43hSW7qRZMJd58XjJpfQ1Qycb85wzofqTGhtayWN_rjt3LY1b5Q8rT7n_MC5aARvTqqTrhWGS35WPd-Ap0jLsoaYHYVC9wn204FB8Gyg6CmXRMNaKAYWR1bQTQELrUvddUs9w4AzerbEEN0cA8zbYaEh-gO7U4ZRYHsohKFk9kRlYhOCf_UO6P4yB8Fh-lJ9GmHO-PU4z6u7y1-3F9f17s_V74ufu3qSxpRauNaAahw49NY741oxam5GtA4aaYQ0g2kHVLJpN23EpuPKQqdxGK02Wqrz6seb7z7FxxVz6RfKDucZAsY199Z2WjbcbuC3I7gOC_p-n2iBdOiPrW3696MO2cE8pi0G5XdMmX_Yf_8mup-eKGH_ljdhRkhu6kVvet0J9QK_YYZq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77952407</pqid></control><display><type>article</type><title>Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>DE BREE, R ; ROOS, J. C ; QUAK, J. J ; DEN HOLLANDER, W ; SNOW, G. B ; VAN DONGEN, G. A. M. S</creator><creatorcontrib>DE BREE, R ; ROOS, J. C ; QUAK, J. J ; DEN HOLLANDER, W ; SNOW, G. B ; VAN DONGEN, G. A. M. S</creatorcontrib><description>So far, mAb E48 is the most promising antibody described for specific targeting of head and neck squamous cell carcinoma (HNSCC)
in patients. On the basis of its more homogeneous reactivity pattern on HNSCC, the novel mAb U36 may be even better suited
for targeting. In this study the biodistribution of mAb U36 was evaluated by radioimmunoscintigraphy (RIS) and biopsy measurements
in 10 patients who were suspected of having neck lymph node metastases from a histologically proven HNSCC and who had been
scheduled to undergo resection of the primary tumor and neck dissection. Patients received 1.8-53.0 mg mAb U36 IgG labeled
with 756 +/- 95 MBq technetium-99m i.v. Preoperatively, palpation, computerized tomography, magnetic resonance imaging, and
RIS were performed. RIS images included planar and single-photon emission computerized tomography images of the head and neck
and planar images of the whole body. The diagnostic findings were recorded per side as well as per lymph node level of the
neck and compared to the histopathological outcome. Radioactivity in blood samples and biopsies from the surgical specimens
were measured. All 10 primary tumors were visualized by RIS. All diagnostic modalities were correct in 7 of 14 tumor-involved
lymph node levels. The missed lymph node metastases comprised micrometastases, small tumor-involved nodes (<9 mm), and tumor-involved
nodes with much necrosis, keratin, or fibrin. There were no false-positive observations with mAb U36. Besides activity uptake
in tumor tissue, only a slight accumulation of activity was observed in the mouth, lungs, liver, spleen, kidneys, and scrotal
area. Biopsies from the surgical specimen showed a high tumor uptake of 20.4 +/- 12.4% of the injected dose/kg (range, 8.0-43.0%
of injected dose/kg), 44 h postinjection. An increase in the mAb dose did not influence uptake of activity in tumor tissue.
The mean tumor:nontumor ratio at this time point was 2.3 for mucosa, 2.8 for blood, 3.0 for bone marrow aspirate, 12.9 for
fat, and 13.0 for muscle tissue. The present clinical study shows that technetium-99m-labeled U36 IgG accumulates selectively
and to a high level in HNSCC. The tumor-targeting results for U36 IgG are comparable to those previously described for E48
IgG. On the basis of the results of ongoing biodistribution studies in which both mAbs E48 and U36, labeled with different
iodine isotopes, are simultaneously evaluated for tumor uptake and retention in HNSCC patients, one of these mAbs will be
selected for future adjuvant radioimmunotherapy trials.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>PMID: 9816020</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Aged ; Antibodies, Monoclonal - pharmacokinetics ; Biological and medical sciences ; Carcinoma, Squamous Cell - diagnostic imaging ; Carcinoma, Squamous Cell - metabolism ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - surgery ; Female ; Head and Neck Neoplasms - diagnostic imaging ; Head and Neck Neoplasms - metabolism ; Head and Neck Neoplasms - pathology ; Head and Neck Neoplasms - surgery ; Humans ; Lymph Nodes - diagnostic imaging ; Lymphatic Metastasis ; Male ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Otorhinolaryngology (head neck, general aspects and miscellaneous) ; Otorhinolaryngology. Stomatology ; Radioimmunodetection ; Radiopharmaceuticals - pharmacokinetics ; Technetium - pharmacokinetics ; Tissue Distribution ; Tomography, Emission-Computed, Single-Photon ; Tumors</subject><ispartof>Clinical cancer research, 1995-06, Vol.1 (6), p.591-598</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3616022$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9816020$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DE BREE, R</creatorcontrib><creatorcontrib>ROOS, J. C</creatorcontrib><creatorcontrib>QUAK, J. J</creatorcontrib><creatorcontrib>DEN HOLLANDER, W</creatorcontrib><creatorcontrib>SNOW, G. B</creatorcontrib><creatorcontrib>VAN DONGEN, G. A. M. S</creatorcontrib><title>Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>So far, mAb E48 is the most promising antibody described for specific targeting of head and neck squamous cell carcinoma (HNSCC)
in patients. On the basis of its more homogeneous reactivity pattern on HNSCC, the novel mAb U36 may be even better suited
for targeting. In this study the biodistribution of mAb U36 was evaluated by radioimmunoscintigraphy (RIS) and biopsy measurements
in 10 patients who were suspected of having neck lymph node metastases from a histologically proven HNSCC and who had been
scheduled to undergo resection of the primary tumor and neck dissection. Patients received 1.8-53.0 mg mAb U36 IgG labeled
with 756 +/- 95 MBq technetium-99m i.v. Preoperatively, palpation, computerized tomography, magnetic resonance imaging, and
RIS were performed. RIS images included planar and single-photon emission computerized tomography images of the head and neck
and planar images of the whole body. The diagnostic findings were recorded per side as well as per lymph node level of the
neck and compared to the histopathological outcome. Radioactivity in blood samples and biopsies from the surgical specimens
were measured. All 10 primary tumors were visualized by RIS. All diagnostic modalities were correct in 7 of 14 tumor-involved
lymph node levels. The missed lymph node metastases comprised micrometastases, small tumor-involved nodes (<9 mm), and tumor-involved
nodes with much necrosis, keratin, or fibrin. There were no false-positive observations with mAb U36. Besides activity uptake
in tumor tissue, only a slight accumulation of activity was observed in the mouth, lungs, liver, spleen, kidneys, and scrotal
area. Biopsies from the surgical specimen showed a high tumor uptake of 20.4 +/- 12.4% of the injected dose/kg (range, 8.0-43.0%
of injected dose/kg), 44 h postinjection. An increase in the mAb dose did not influence uptake of activity in tumor tissue.
The mean tumor:nontumor ratio at this time point was 2.3 for mucosa, 2.8 for blood, 3.0 for bone marrow aspirate, 12.9 for
fat, and 13.0 for muscle tissue. The present clinical study shows that technetium-99m-labeled U36 IgG accumulates selectively
and to a high level in HNSCC. The tumor-targeting results for U36 IgG are comparable to those previously described for E48
IgG. On the basis of the results of ongoing biodistribution studies in which both mAbs E48 and U36, labeled with different
iodine isotopes, are simultaneously evaluated for tumor uptake and retention in HNSCC patients, one of these mAbs will be
selected for future adjuvant radioimmunotherapy trials.</description><subject>Aged</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Squamous Cell - diagnostic imaging</subject><subject>Carcinoma, Squamous Cell - metabolism</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - surgery</subject><subject>Female</subject><subject>Head and Neck Neoplasms - diagnostic imaging</subject><subject>Head and Neck Neoplasms - metabolism</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Head and Neck Neoplasms - surgery</subject><subject>Humans</subject><subject>Lymph Nodes - diagnostic imaging</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Otorhinolaryngology (head neck, general aspects and miscellaneous)</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Radioimmunodetection</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Technetium - pharmacokinetics</subject><subject>Tissue Distribution</subject><subject>Tomography, Emission-Computed, Single-Photon</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkM1q3TAQhU1pSdK0j1DQonRn0I8l2csSmqRwoRCStRlL43hSW7qRZMJd58XjJpfQ1Qycb85wzofqTGhtayWN_rjt3LY1b5Q8rT7n_MC5aARvTqqTrhWGS35WPd-Ap0jLsoaYHYVC9wn204FB8Gyg6CmXRMNaKAYWR1bQTQELrUvddUs9w4AzerbEEN0cA8zbYaEh-gO7U4ZRYHsohKFk9kRlYhOCf_UO6P4yB8Fh-lJ9GmHO-PU4z6u7y1-3F9f17s_V74ufu3qSxpRauNaAahw49NY741oxam5GtA4aaYQ0g2kHVLJpN23EpuPKQqdxGK02Wqrz6seb7z7FxxVz6RfKDucZAsY199Z2WjbcbuC3I7gOC_p-n2iBdOiPrW3696MO2cE8pi0G5XdMmX_Yf_8mup-eKGH_ljdhRkhu6kVvet0J9QK_YYZq</recordid><startdate>19950601</startdate><enddate>19950601</enddate><creator>DE BREE, R</creator><creator>ROOS, J. C</creator><creator>QUAK, J. J</creator><creator>DEN HOLLANDER, W</creator><creator>SNOW, G. B</creator><creator>VAN DONGEN, G. A. M. S</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19950601</creationdate><title>Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer</title><author>DE BREE, R ; ROOS, J. C ; QUAK, J. J ; DEN HOLLANDER, W ; SNOW, G. B ; VAN DONGEN, G. A. M. S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h266t-1c86a34caced7dc6c81f506fe7ca426126b68be32486c8fe49037a95ebf756523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Squamous Cell - diagnostic imaging</topic><topic>Carcinoma, Squamous Cell - metabolism</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - surgery</topic><topic>Female</topic><topic>Head and Neck Neoplasms - diagnostic imaging</topic><topic>Head and Neck Neoplasms - metabolism</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Head and Neck Neoplasms - surgery</topic><topic>Humans</topic><topic>Lymph Nodes - diagnostic imaging</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Otorhinolaryngology (head neck, general aspects and miscellaneous)</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Radioimmunodetection</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Technetium - pharmacokinetics</topic><topic>Tissue Distribution</topic><topic>Tomography, Emission-Computed, Single-Photon</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DE BREE, R</creatorcontrib><creatorcontrib>ROOS, J. C</creatorcontrib><creatorcontrib>QUAK, J. J</creatorcontrib><creatorcontrib>DEN HOLLANDER, W</creatorcontrib><creatorcontrib>SNOW, G. B</creatorcontrib><creatorcontrib>VAN DONGEN, G. A. M. S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DE BREE, R</au><au>ROOS, J. C</au><au>QUAK, J. J</au><au>DEN HOLLANDER, W</au><au>SNOW, G. B</au><au>VAN DONGEN, G. A. M. S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>1995-06-01</date><risdate>1995</risdate><volume>1</volume><issue>6</issue><spage>591</spage><epage>598</epage><pages>591-598</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>So far, mAb E48 is the most promising antibody described for specific targeting of head and neck squamous cell carcinoma (HNSCC)
in patients. On the basis of its more homogeneous reactivity pattern on HNSCC, the novel mAb U36 may be even better suited
for targeting. In this study the biodistribution of mAb U36 was evaluated by radioimmunoscintigraphy (RIS) and biopsy measurements
in 10 patients who were suspected of having neck lymph node metastases from a histologically proven HNSCC and who had been
scheduled to undergo resection of the primary tumor and neck dissection. Patients received 1.8-53.0 mg mAb U36 IgG labeled
with 756 +/- 95 MBq technetium-99m i.v. Preoperatively, palpation, computerized tomography, magnetic resonance imaging, and
RIS were performed. RIS images included planar and single-photon emission computerized tomography images of the head and neck
and planar images of the whole body. The diagnostic findings were recorded per side as well as per lymph node level of the
neck and compared to the histopathological outcome. Radioactivity in blood samples and biopsies from the surgical specimens
were measured. All 10 primary tumors were visualized by RIS. All diagnostic modalities were correct in 7 of 14 tumor-involved
lymph node levels. The missed lymph node metastases comprised micrometastases, small tumor-involved nodes (<9 mm), and tumor-involved
nodes with much necrosis, keratin, or fibrin. There were no false-positive observations with mAb U36. Besides activity uptake
in tumor tissue, only a slight accumulation of activity was observed in the mouth, lungs, liver, spleen, kidneys, and scrotal
area. Biopsies from the surgical specimen showed a high tumor uptake of 20.4 +/- 12.4% of the injected dose/kg (range, 8.0-43.0%
of injected dose/kg), 44 h postinjection. An increase in the mAb dose did not influence uptake of activity in tumor tissue.
The mean tumor:nontumor ratio at this time point was 2.3 for mucosa, 2.8 for blood, 3.0 for bone marrow aspirate, 12.9 for
fat, and 13.0 for muscle tissue. The present clinical study shows that technetium-99m-labeled U36 IgG accumulates selectively
and to a high level in HNSCC. The tumor-targeting results for U36 IgG are comparable to those previously described for E48
IgG. On the basis of the results of ongoing biodistribution studies in which both mAbs E48 and U36, labeled with different
iodine isotopes, are simultaneously evaluated for tumor uptake and retention in HNSCC patients, one of these mAbs will be
selected for future adjuvant radioimmunotherapy trials.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>9816020</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 1995-06, Vol.1 (6), p.591-598 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77952407 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Aged Antibodies, Monoclonal - pharmacokinetics Biological and medical sciences Carcinoma, Squamous Cell - diagnostic imaging Carcinoma, Squamous Cell - metabolism Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - surgery Female Head and Neck Neoplasms - diagnostic imaging Head and Neck Neoplasms - metabolism Head and Neck Neoplasms - pathology Head and Neck Neoplasms - surgery Humans Lymph Nodes - diagnostic imaging Lymphatic Metastasis Male Medical sciences Middle Aged Neoplasm Staging Otorhinolaryngology (head neck, general aspects and miscellaneous) Otorhinolaryngology. Stomatology Radioimmunodetection Radiopharmaceuticals - pharmacokinetics Technetium - pharmacokinetics Tissue Distribution Tomography, Emission-Computed, Single-Photon Tumors |
| title | Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A40%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radioimmunoscintigraphy%20and%20biodistribution%20of%20technetium-99m-labeled%20monoclonal%20antibody%20U36%20in%20patients%20with%20head%20and%20neck%20cancer&rft.jtitle=Clinical%20cancer%20research&rft.au=DE%20BREE,%20R&rft.date=1995-06-01&rft.volume=1&rft.issue=6&rft.spage=591&rft.epage=598&rft.pages=591-598&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E77952407%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77952407&rft_id=info:pmid/9816020&rfr_iscdi=true |